Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping | MicrobiomeTrials← Back to trialsNCT07250737
Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping
AVAILABLEEXPANDED_ACCESS
Trial Details
Locations- University of Alabama, Birmingham, Alabama, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Rare Disease Research, Kissimmee, Florida, United States
- Rare Disease Research, Atlanta, Georgia, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- UMass Memorial Health Care, Worcester, Massachusetts, United States
- Gillette Children's, Saint Paul, Minnesota, United States
- Washington University, St Louis, Missouri, United States
- Rare Disease Research, Iselin, New Jersey, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Prisma Health-Midlands Children's Hospital, Columbia, South Carolina, United States
- University of Vermont Medical Center, Burlington, Vermont, United States
Other microbiome trials you might be interested in
Obstetrical Brachial Plexus Palsy
The purpose of this prospective work is to study the consequences of obstetrical brachial plexus paralysis on the rotato…
Montpellier, FranceCompleted Jun 25, 2025
Muscle Wasting in Critically Ill
Acute skeletal muscle wasting in ICU patients is associated with functional impairment and with increased risk of death.…
Basel, SwitzerlandCompleted Feb 13, 2026